HC Wainwright reaffirmed their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE - Free Report) in a report issued on Monday morning,Benzinga reports. They currently have a $5.75 price objective on the stock.
Separately, BTIG Research started coverage on shares of VYNE Therapeutics in a research note on Monday, November 18th. They issued a "buy" rating and a $8.00 target price for the company.
Read Our Latest Research Report on VYNE Therapeutics
VYNE Therapeutics Stock Performance
NASDAQ:VYNE traded up $0.54 during mid-day trading on Monday, hitting $4.00. 284,514 shares of the company's stock traded hands, compared to its average volume of 159,001. The company has a market cap of $59.00 million, a PE ratio of -4.65 and a beta of 1.30. The firm's 50 day simple moving average is $2.89 and its 200 day simple moving average is $2.28. VYNE Therapeutics has a 1 year low of $1.57 and a 1 year high of $4.00.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in VYNE Therapeutics stock. Lynx1 Capital Management LP bought a new stake in VYNE Therapeutics Inc. (NASDAQ:VYNE - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 16,194 shares of the company's stock, valued at approximately $32,000. VYNE Therapeutics comprises about 0.0% of Lynx1 Capital Management LP's portfolio, making the stock its 17th biggest holding. Lynx1 Capital Management LP owned 0.11% of VYNE Therapeutics as of its most recent filing with the Securities & Exchange Commission. 83.78% of the stock is currently owned by institutional investors.
VYNE Therapeutics Company Profile
(
Get Free Report)
VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.
Recommended Stories
Before you consider VYNE Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and VYNE Therapeutics wasn't on the list.
While VYNE Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
